ArticleLung2026
Sample Adequacy PD-L1 and NGS in NSCLC: Shape-Sensing Robotic Assisted Bronchoscopy Versus CT Guided Lung Biopsy.
Article in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRoutine assessment of programmed death-ligand 1 (PD-L1) expression and comprehensive next-generation sequencing (NGS) is recommended to guide treatment selection in patients with non-small cell lung cancer (NSCLC). Obtaining adequate tissue for biomarker and molecular analyses is therefore essential. This study compared sample adequacy for PD-L1 and NGS testing between shape-sensing robotic-assisted bronchoscopy (ssRAB) and computed tomography-guided transthoracic lung biopsy (CTTB) in patients with NSCLC.
methodsWe conducted a single-center retrospective study of patients with NSCLC who underwent biopsy of PPL by ssRAB or CTTB between June 2020 and December 2025. Demographic, procedural, pathological, biomarker and molecular data were extracted from electronic medical records, and descriptive statistics analysis and multivariable logistic regression were performed.
resultsA total of 402 patients were included, comprising 198 in the ssRAB cohort and 204 in the CTTB cohort. ssRAB demonstrated significantly higher sample adequacy rates than CTTB for both PD-L1 (98.8% vs. 90.6%, p < 0.001) and NGS testing (92.3% vs. 79.1%, p = 0.005). In multivariable logistic regression analyses, ssRAB was independently associated with higher odds of PD-L1 sample adequacy (adjusted OR 11.48, 95% CI 2.89-78.30; p = 0.002) and NGS sample adequacy (adjusted OR 4.01, 95% CI 1.64-11.40; p = 0.004) compared with CTTB. In a separate model evaluating biopsy tools, cryobiopsy use was independently associated with higher odds of PD-L1 adequacy (adjusted OR 16.54, 95% CI 2.92-317.65; p = 0.010) and NGS adequacy (adjusted OR 5.83, 95% CI 1.93-25.39; p = 0.006) compared with non-cryobiopsy sampling.
conclusionsssRAB-acquired specimens were associated with higher rates of PD-L1 and NGS sample adequacy than CTTB-acquired specimens in patients with NSCLC. Future prospective studies are needed to better understand the procedural and specimen-related factors underlying these differences.
Indexed as
Identifiers
42875565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.